NCT01002950

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Kubota Vision Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.

Conditions

• Dry Age-related Macular Degeneration
• Geographic Atrophy

Interventions

Type	Name	Description
DRUG	ACU-4429	ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
DRUG	Matching placebo	Matching placebo tablets taken orally once daily for 90 days

Timeline

• Start date: 2009-10-01
• Primary completion: 2012-06-01
• Completion: 2012-10-01
• First posted: 2009-10-28
• Last updated: 2014-03-11

Locations

12 sites across 1 country: United States